Basic Info.

B7-33 is a novel, synthetic compound that was first discovered and developed by a team of researchers at the Monash University in Australia. The development of B7-33 was based on the discovery of the relaxin receptor 1 (RXFP1) and the recognition of its potential as a therapeutic target for a wide range of diseases and conditions.

The research team, led by Professor David Handelsman, first synthesized B7-33 in the early 2010s as part of their efforts to develop a functionally selective agonist for RXFP1. This compound was then tested in a series of in vitro and in vivo studies, which demonstrated its potential as a treatment for hypertension, kidney disease, and heart failure. The team's research on B7-33 was published in several scientific journals, including the Journal of Biological Chemistry and the Journal of Hypertension. 

These publications highlighted the compound's unique mechanism of action and its potential as a treatment option for patients.

 

---

Our factory

“Strength builds the foundation, and excellent services reach all over the world.” Create win-win situation with customers